Şebnem ŞENOL, Özlem TÜNGER, Çiğdem Banu ÇETİN, Gönül DİNÇ HORASAN, Deniz ÖZER TÜRK

Colistin efficacy in the treatment of multidrug-resistant and extremelydrug-resistant gram-negative bacterial infections

Background/aim: Colistin is used as a salvage therapy for multidrug-resistant and extremely drug-resistant gram-negative bacterial infections. Our aim was to evaluate colistin efficiency and toxicity in the treatment of these resistant gram-negative bacterial infections. Materials and methods: This is a retrospective study carried out in a tertiary care hospital during 2011 2013. Study data were collected from the medical records and consultations of the infectious diseases clinic. Results: The study group included 158 patients with nosocomial infections and 136 (86.1%) of them were hospitalized in the ICU. Respiratory tract infections were the most commonly observed ones (n = 103, 65.2%). The most frequently isolated microorganism was Acinetobacter baumannii (72.2%). A total of 98 (62.0%) patients had clinical cure. There was no statistically significant difference between monotherapy (n = 3/6, 50.0%) and combination therapies (n = 95/152, 62.5%) according to clinical response. Underlying ultimately fatal disease, previous renal disease, and total parenteral nutrition were independent risk factors for poor clinical response. Nephrotoxicity developed in 80 (50.6%) patients and clinical cure was statistically unrelated with nephrotoxicity. Conclusion: Colistin may be used as an effective agent for multidrug-resistant and extremely drug-resistant gram-negative bacterial infections with close monitoring of renal functions, especially for older and critically ill patients

PDF

___

1. Yahav D, Farbman L, Leibovici L, Paul M. Colistin: new lessons on an old antibiotic. Clin Microbiol Infect 2012; 18: 18-29.
2. Karaiskos I, Giamarellou H. Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother 2014; 15: 1351-1370.
3. Tukenmez TE, Koltka EN, Dogru A, Orhon ZN, Gura N, Vahaboglu H. Impact of the initiation time of colistin treatment for Acinetobacter infections. J Infect Chemother 2013; 19: 703- 708.
4. Falagas ME, Rafailidis PI, Ioannidou E, Alexiou VG, Matthaiou DK, Karageorgopoulos DE, Kapaskelis A, Nikita D, Michalopoulos A. Colistin therapy for microbiologically documented multidrug-resistant gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents 2010; 35: 194-199.
5. Kwon JA, Lee JE, Huh W, Peck KR, Kim YG, Kim DJ, Oh HY. Predictors of acute kidney injury associated with intravenous colistin treatment. Int J Antimicrob Agents 2010; 35: 473-477.
6. Gul S, Kuscu F, Aydemir H, Ozturk DB, Deveci O, Duygu F, Kacmaz B, Yaman F, Aslan E. Risk factors for colistin-associated acute kidney injury: a multicenter study from Turkey. Jpn J Infect Dis 2016; 69: 109-112.
7. McCabe W, Jackson G. Gram-negative bacteremia: I. Etiology and ecology. Arch Intern Med 1962; 110: 847-855.
8. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure--definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8: 204-212.
9. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988; 16: 128-140.
10. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, OlssonLiljequist B et al. Multidrug-resistant, extensively drugresistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18: 268-281.
11. Kallel H, Bahloul M, Hergafi L, Akrout M, Ketata W, Chelly H, Hamida CB, Rekik N, Hammami A, Bouaziz M. Colistin as a salvage therapy for nosocomial infections caused by multidrug resistant bacteria in the ICU. Int J Antimicrob Agents 2006; 28: 366-369.
12. Koomanachai P, Tiengrim S, Kiratisin P, Thamlikitkul V. Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand. Int J Infect Dis 2007; 11: 402-406.
13. Montero M, Horcajada JP, Sorlí L, Alvarez-Lerma F, Grau S, Riu M, Sala M, Knobel H. Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections. Infection 2009; 37: 461-465.
14. Cheng CY, Sheng WH, Wang JT, Chen YC, Chang SC. Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections. Int J Antimicrob Agents 2010; 35: 297-300.
15. Binh NG, Hayakawa K, Co DX, Tuan ND, Anh NH, Thuy NT, Phuong DM, Huong NT, Thuy PT, Chau NQ et al. The efficacy and nephrotoxicity associated with colistin use in an intensive care unit in Vietnam: use of colistin in a population of lower body weight. Int J Infect Dis 2015; 35: 18-23.
16. Zhang H, Zhang Q. Clinical efficacy and safety of colistin treatment in patients with pulmonary infection caused by Pseudomonas aeruginosa or Acinetobacter baumannii: a meta-analysis. Arch Med Sci 2015; 11: 34-42.
17. Ouderkirk JP, Nord JA, Turett GS, Kislak JW. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. Antimicrob Agents Chemother 2003; 47: 2659-2662.
18. Oliveira MS, Prado GV, Costa SF, Grinbaum RS, Levin AS. Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother 2008; 61: 1369- 1375.
19. Linden PK, Kusne S, Coley K, Fontes P, Kramer DJ, Paterson D. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis 2003; 37: e154-e160.
20. Inchai J, Liwsrisakun C, Theerakittikul T, Chaiwarith R, Khositsakulchai W, Pothirat C. Risk factors of multidrugresistant, extensively drug-resistant and pandrug-resistant Acinetobacter baumannii ventilator-associated pneumonia in a medical intensive care unit of University Hospital in Thailand. J Infect Chemother 2015; 21: 570-574.
21. Petrosillo N, Ioannidou E, Falagas ME. Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies. Clin Microbiol Infect 2008; 14: 816-827.
22. López-Cortés LE, Cisneros JM, Fernández-Cuenca F, Bou G, Tomás M, Garnacho-Montero J, Pascual A, Martínez-Martínez L, Vila J, Pachón J et al. Monotherapy versus combination therapy for sepsis due to multi-drug resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort. J Antimicrob Chemother 2014; 69: 3119-3126.
23. Li J, Rayner CR, Nation RL, Owen RJ, Spelman D, Tan KE, Liolios L. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2006; 50: 2946-2950.
24. Yilmaz GR, Guven T, Guner R, Kocak Tufan Z, Izdes S, Tasyaran MA, Acikgoz ZC. Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilatorassociated pneumonia. J Infect Dev Ctries 2015; 9: 476-485.
25. Batirel A, Balkan II, Karabay O, Agalar C, Akalin S, Alici O, Alp E, Altay FA, Altin N, Arslan F et al Comparison of colistincarbapenem, colistinsulbactam, and colistin plus other antibacterial agents for the treatment of extremely drugresistant Acinetobacter baumannii bloodstream infections. Eur J Clin Microbiol Infect Dis 2014; 33: 1311-1322.
26. Dean AG, Sullivan KM, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health. Atlanta, GA, USA: Emory University; 2013. Available online at http://www. openepi.com/Power/PowerCross.htm.
27. Ordooei Javan A, Shokouhi S, Sahraei Z. A review on colistin nephrotoxicity. Eur J Clin Pharmacol 2015; 71: 801- 810.
28. Wadia S, Tran B. Colistin-mediated neurotoxicity. BMJ Case Rep 2014; 2014: bcr2014205332.
29. Justo JA, Bosso JA. Adverse reactions associated with systemic polymyxin therapy. Pharmacotherapy 2015; 35: 28-33.